Brief Title
Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers
Official Title
Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers
Brief Summary
To clarify the critical role of glycosyltransferases, altered Mucins, and RTKs in human
ovarian and endometrial neoplasms, the study will examine the immunohistochemical expression
profiles of glycosyltransferases, Mucins and receptor tyrosin kinases (RTKs) family in
various stages and/or histologic subtypes of human ovarian and endometrial neoplasms and
tissue microarrays.
Detailed Description
Glycosylation is a widely utilized chemical modification of proteins and lipids in mammalian
cells during which saccharide units are covalently attached to the target structures and then
sequentially elongated and branched - reactions facilitated by a large number of various
glycosyltransferases. Alterations in this process have been associated with malignant
transformation. To clarify the critical role of glycosyltransferases, altered Mucins (MUC),
and RTKs in human ovarian and endometrial neoplasms, the study will examine the
immunohistochemical expression profiles of glycosyltransferases (including
β-1,4-Galactosyltransferase 1 (B4GALT1), β-1,4-Galactosyltransferase 3 (B4GALT3),
β-1,4-N-Acetyl-Galactosaminyl Transferase 3 (B4GALNT3), Polypeptide
N-Acetylgalactosaminyltransferase 2 (GALNT2), Polypeptide N-Acetylgalactosaminyltransferase 6
(GALNT6), β1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III),
β1,4-N-acetylglucosaminyltransferase V (GlcNAcT-V), and Glycoprotein-N-Acetylgalactosamine
3-Beta-Galactosyltransferase 1 (C1GALT1), Mucins (including MUC1, MUC3, MUC15, and MUC20) and
receptor tyrosin kinases (RTKs) family (including epidermal growth factor receptor (EGFR),
Src, VEGFR, and c-Met) in various stages and/or histologic subtypes of human ovarian and
endometrial neoplasms and tissue microarrays, and compare them with clinicopathologic factors
including outcome of the patients.
Study Type
Observational
Primary Outcome
Measure the Immunohistochemistry (IHC) expression
Condition
Carcinogenesis
Study Arms / Comparison Groups
Stage I, II, III, IV ovarian cancer
Description: Stage I, II, III, IV ovarian cancer receive treatment in National Taiwan University Hospital
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
250
Start Date
May 2016
Completion Date
August 2017
Primary Completion Date
August 2016
Eligibility Criteria
Inclusion Criteria:
- Ovarian and endometrial cancer patients receiving operation in National Taiwan
University Hospital
Exclusion Criteria:
- Recurrence or non-operable patients
Gender
Female
Ages
20 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Chi-Hau Chen, MD, PhD, +886-972651980, [email protected]
Administrative Informations
NCT ID
NCT02638402
Organization ID
201405068RINA
Responsible Party
Sponsor
Study Sponsor
National Taiwan University Hospital
Study Sponsor
Chi-Hau Chen, MD, PhD, Principal Investigator, National Taiwan University Hospital
Verification Date
May 2016